RNA Gains Genetic Medicine Momentum with News from Orbital, MiNA, BioMarin

Orbital’s $270 million Series A and MiNA’s Therapeutics’ collaboration with BioMarin Pharmaceutical bring RNA medicines closer to treating human disease.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Redmile ,Leicestershire ,Abu Dhabi ,Abuz Aby ,United Arab Emirates ,Alexandria ,Al Iskandariyah ,Egypt ,Kevin Eggan ,Giuseppe Ciaramella ,Redmile Group ,Globe Platinum Fund Group ,Abu Dhabi Growth Fund , ,Orbital Therapeutics ,Newpath Partners ,Moore Strategic Ventures ,Casdin Capital ,Agent Capital ,Alexandria Venture Investments ,Rellim Capital Management ,Heritage Medical Systems ,Biomarin Pharmaceutical ,